Vanguard (ANIK) discloses 695,697 shares, a 5.19% stake (Schedule 13G)
Rhea-AI Filing Summary
Anika Therapeutics Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 695,697 shares of Common Stock, representing 5.19% of the class. The filing shows sole voting power of 89,920 shares and sole dispositive power for 695,697 shares.
The filing is submitted on behalf of Vanguard Capital Management and affiliated business divisions; the signature is by Ashley Grim, Head of Global Fund Administration.
Positive
- None.
Negative
- None.
Insights
Vanguard holds a >5% passive stake in Anika Therapeutics.
Vanguard Capital Management reports beneficial ownership of 695,697 shares (5.19%), a threshold that requires public disclosure under Schedule 13G reporting rules. The filing attributes voting and dispositive powers across Vanguard entities.
Holding this size can appear on investor ownership screens; subsequent 13G/A or 13D filings would indicate changes in intentions or activism. Future filings may update percentages if positions change.
Filing follows passive investor disclosure guidance.
The statement cites SEC Release No. 34-39538 and lists affiliated Vanguard entities that exercise dispositive power, consistent with aggregated reporting for investment managers. The signature block shows an authorized officer certified the report.
This Schedule 13G signals passive reporting status under the Exchange Act; any shift toward active influence would typically trigger a different reporting form.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficial ownership financial
Dispositive power regulatory
Sole voting power regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.